Canaccord Genuity Group Raises Natera (NASDAQ:NTRA) Price Target to $145.00

Natera (NASDAQ:NTRA) had its price target boosted by Canaccord Genuity Group from $130.00 to $145.00 in a research report released on Tuesday, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

NTRA has been the subject of several other research reports. Jefferies Financial Group began coverage on Natera in a report on Monday, June 3rd. They set a buy rating and a $142.00 price objective for the company. BTIG Research raised their price objective on shares of Natera from $125.00 to $135.00 and gave the company a buy rating in a research note on Friday, August 9th. Piper Sandler boosted their price objective on Natera from $120.00 to $150.00 and gave the stock an overweight rating in a report on Tuesday, August 13th. StockNews.com upgraded Natera from a sell rating to a hold rating in a report on Tuesday, August 20th. Finally, Robert W. Baird upped their price target on Natera from $117.00 to $120.00 and gave the stock an outperform rating in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, Natera currently has an average rating of Moderate Buy and an average price target of $120.07.

Natera Stock Down 2.2 %

Shares of NASDAQ:NTRA opened at $116.25 on Tuesday. The business’s 50-day moving average is $110.81 and its 200-day moving average is $100.09. Natera has a 1 year low of $36.90 and a 1 year high of $124.83. The company has a market capitalization of $14.28 billion, a price-to-earnings ratio of -37.26 and a beta of 1.48. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period in the prior year, the firm earned ($0.97) earnings per share. Natera’s revenue was up 58.1% on a year-over-year basis. Equities research analysts predict that Natera will post -2.43 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 6,105 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $111.61, for a total transaction of $681,379.05. Following the completion of the sale, the chief executive officer now owns 213,351 shares in the company, valued at $23,812,105.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Steven Leonard Chapman sold 6,105 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05. Following the transaction, the chief executive officer now owns 213,351 shares of the company’s stock, valued at approximately $23,812,105.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Sheena sold 12,000 shares of Natera stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,388 shares of company stock valued at $10,205,064. 7.60% of the stock is owned by insiders.

Institutional Trading of Natera

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Natera by 0.7% in the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after acquiring an additional 72,848 shares during the period. Farallon Capital Management LLC lifted its holdings in Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Natera by 6.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock worth $259,634,000 after purchasing an additional 148,917 shares during the period. Duquesne Family Office LLC grew its holdings in Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after buying an additional 45,500 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Natera by 7.1% during the fourth quarter. Principal Financial Group Inc. now owns 1,703,615 shares of the medical research company’s stock valued at $106,714,000 after buying an additional 112,825 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.